Viral protein Nef enables a step toward off-the-shelf CAR T cell therapy for cancer
CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...
News Medical4d
Cancer-fighting virus T-VEC helps shrink tough-to-treat skin tumors
Talimogene laherparepvec (T-VEC) demonstrates efficacy in cutaneous BCC, enhancing resectability and altering immune cell ...
Biomednewsbreaks Calidi Biotherapeutics Inc. (NYSE American: CLDI) To Host Investor Webinar On Feb. 5
Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company advancing targeted antitumor virotherapies, will host an invest ...
emjreviews.com4d
New Trial Advances Basal Cell Carcinoma Treatment
A phase II trial reports success with an innovative immunotherapy for difficult-to-resect basal cell carcinoma, reducing ...
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on February 5 ...
PharmiWeb7d
Reithera and Sillajen Partnership Announced
ReiThera is proud to announce a new partnership with SillaJen through a comprehensive Master Service Agreement (MSA), which establishes ReiThera as the manufacturing partner for SillaJen’s innovative ...
BioWorld7d
IL-12-armed oncolytic vaccinia virus shows activity in models of lung cancer
Researchers from Zhengzhou University and affiliated organizations presented the development and preclinical characterization of VVL-12, an oncolytic vaccinia virus (VV) for the treatment of lung ...
ENDPOINTS NEWS9d
Boehringer merges can­cer vac­cine and on­colyt­ic virus teams; Dan­tari sells off as­sets
Boehringer Ingelheim merges AMAL and ViraTherapeutics cancer units, Dantari sells assets to Adanate, Madrona raises $770M, and Abdera adds JJDC and Foresite as investors.
Investing11d
Oncolytic virus therapies rapidly expanding, primarily focused on solid tumour applications, says Novotech
A new report from Novotech reveals the OV market is expanding at pace, with a compounding annual growth rate of 14.2% between 2019 and 2024. More than 95% of ongoing trials involving oncolytic viruses ...
Novotech Releases Comprehensive Report on Oncolytic Virus Therapy
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to ...
Business Insider12d
Transgene to Participate in the Biomed Forum Investor Conference
The Company’s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 ...
Business Insider13d
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies ... proprietary strain of ...